Sanofi, Alnylam restructure RNAi therapeutics deal

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) gained global development and commercialization rights to transthyretin (TTR)-mediated amyloidosis candidates patisiran (ALN-TTR02) and ALN-TTRsc02 after it and Sanofi (Euronext:SAN; NYSE:SNY) amended their 2012 deal. The pharma and its Sanofi Genzyme unit

Read the full 369 word article

User Sign In